In consultation: Guidance and quality standards
Showing 1 to 7 of 7
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256] | Draft guidance | Technology appraisal guidance | |
| Leadless cardiac pacemaker implantation for bradyarrhythmias | Interventional procedure consultation | Interventional procedures guidance | |
| Low energy contact X-ray brachytherapy for rectal cancer | Interventional procedure consultation | Interventional procedures guidance | |
| Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394] | Draft guidance | Technology appraisal guidance | |
| Teprotumumab for treating thyroid eye disease [ID6432] | Draft guidance | Technology appraisal guidance | |
| Pegzilarginase for treating arginase-1 deficiency [ID4029] | Draft guidance | Highly specialised technology | |
| Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211] | Draft guidance | Technology appraisal guidance |